News | March 14, 2026
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The protections extend through at least 2035, with the potential for further extensions
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Germany will be the first launch market
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Subscribe To Our Newsletter & Stay Updated
